ClinicalTrials.gg
RecruitingNCT07620535DCaFUpdated Nov 16, 2026

Decision Counseling and Follow-up for Shield+ Patients

An observational study in Colo-rectal Cancer, sponsored by Guardant Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Guardant Health, Inc. · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Planned enrollment
74th of 181
350 · median 220
Started
2026
with 30 others
Observational
181 of 1,123
30 open now
Primary completion
2027-12
later than 114 of 187 live
Registered
1,112th of 1,123
by date

Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 74th largest by planned enrollment of the 181 observational ones that give a count, is one of 31 that started in 2026, is one of 181 observational ones, reaches primary completion later than 114 of the 187 other live ones, and was the 1,112th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

109 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,123 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Prospective, observational, minimal-risk study evaluating decision-making, decisional conflict, intention to undergo complete diagnostic evaluation (CDE), and colonoscopy completion after a positive Shield TM blood-based colorectal cancer screening test result.

Read the detailed description

The DCaF study uses a prospective, observational design to characterize how patients make decisions following a Shield(+) screening result and to assess real-world adherence to recommended diagnostic colonoscopy. Because the intervention of interest is the patient's naturally occurring decision-making process-not the performance of the test itself-a non-interventional design is methodologically appropriate and minimizes participant burden. Incorporating decision counseling allows systematic evaluation of changes in preference, decisional conflict, and intention, while linkage to real-world evidence (RWE) claims data provides an efficient and objective method for determining colonoscopy completion. This approach enables the study to identify behavioral, clinical, and system-level factors associated with follow-up adherence without altering standard clinical care.

03

Conditions studied

  • Colo-rectal Cancer

Browse trials for

Keywords

  • Colo-rectal Cancer
  • Screening
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults with a recent clinically ordered Shield™ test result who received a positive (abnormal) screening (Shield+) result.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is 45-75 years old at the time of ShieldTM test order.
  • Participant has a valid Shield(+) test result.
  • Participant is willing and able to complete the process
  • Participant is able to complete the informed consent process and decision counseling session in English

Exclusion criteria

Exclusion Criteria:

  • Participant is already enrolled in another Guardant Health, Inc. clinical study or has received a positive MCD result for a cancer type other than CRC.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • SHIELD Positive with Completed Colonoscopy

    Patients who are intending to undergo a complete a diagnostic evaluation

    Behavioral: Decision Counseling Session

Interventions

  • BehavioralDecision Counseling Session

    During the decision counseling session, JH research staff will review the Complete Diagnostic Evaluation (CDE) infographic and use an online survey to guide the participant through a telephone encounter that involves the identification of patient goals that are likely to affect their decision to have CDE and not to have CDE.

06

What researchers measure

Primary outcomes

  1. CDE Decisional Conflict

    Determine the level of preference for, decisional conflict related to, intention to have CDE following a Shield+ result at baseline and after decision counseling and assess change.

    Time frame: From Enrollment to the end of study at 6 months

  2. Factors for CDE Decisional Conflict

    Identify factors associated with CDE decisional conflict, intention, and preference following a positive Shield result.

    Time frame: From Enrollment to End of Study at 6 months

  3. Factors for Changes in CDE Decisional Conflict

    Identify factors associated with change in CDE preference, decisional conflict, intention, and preference.

    Time frame: From Enrollment to End of Study at 6 months

07

Study locations

1 of 1 sites recruiting
  • Jefferson Center
    Philadelphia, Pennsylvania 19114, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 225 observational studies under Colonic Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 16 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Aug 11, 2026was Jun 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Jefferson Center is now Recruiting
Nov 16, 2026
Start date
Jun 2026→Aug 11, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Jefferson Center is now Recruiting
    Start date Jun 2026→Aug 11, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07620535
Lead sponsor
Guardant Health, Inc.
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Aug 11, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Director of Clinical Trial Operations
Contact
dcaf@guardanthealth.com
855-698-8887

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion